Vyuhpharma

Sungen *(FDA , FTD)*

FDA grants Fast Track designation to Sungen Biomedical's SGC001 mAb for acute myocardial infarction

---

Sermonix + Regor *(Partnership)*

Sermonix and Regor partner to enhance rCARD platform for advancing breast oncology therapeutics

---

Palatin *(FDA, ODD)*

FDA grants Orphan Drug Status to Palatin's PL7737 for treating obesity from leptin receptor deficiency

---

Vast *(FDA, QIDP)*

FDA grants QIDP designation to Vast's ALX1 for targeting pseudomonas and other critical pathogens

Vyuhpharma

GV20 + MTPC *(Agreement)*

GV20 Therapeutics enters collaboration with Mitsubishi Tanabe to advance next-gen ADCs for novel cancer targets

---

Dermata *(Clinical trial, Phase 3)*

Dermata's XYNGARI™ achieves primary endpoints with statistically and clinically significant improvement in acne

---

Novo Nordisk *(Clinical trial, Phase 3)*

Novo Nordisk's oral semaglutide 14 mg shows 14% reduction in cardiovascular risk in SOUL trial

---

Novartis *(FDA, Approval)*

Novartis secures FDA nod for earlier use of Pluvicto® in PSMA-positive metastatic prostate cancer

Vyuhpharma

PTC Therapeutics *(CHMP, EMA)*

European Commission upholds CHMP Opinion, declines renewal of PTC Therapeutics' Translarna™ authorization

---

IASO Bio *(ISAF, NDA)*

Macao's ISAF approves IASO Bio's equecabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma after ≥3 prior therapies

---

IDEAYA Biosciences *(FDA, BTD)*

IDEAYA Biosciences receives FDA Breakthrough Therapy Designation for darovasertib as neoadjuvant monotherapy in uveal melanoma

---

Halozyme *(CHMP, EMA)*

Halozyme announces positive CHMP opinion for SC Opdivo® with ENHANZE® in multiple solid tumor indications